臨床試験の世界市場2020-2027:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別、疾患別

◆英語タイトル:Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20JN075
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年5月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2週間)
◆調査対象地域:クローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥618,800見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥722,800見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥930,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、臨床試験の世界市場を調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場の要因・動向・範囲、フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)分析、研究デザイン別分析、地域別分析、競争分析など、今後の市場展望をまとめております。
・調査手法・範囲
・エグゼクティブサマリー
・市場の要因・動向・範囲
・臨床試験の世界市場規模:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)
・臨床試験の世界市場規模:研究デザイン別
・臨床試験の世界市場規模:地域別
・競争分析
【レポートの概要】

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.9 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to exhibit a CAGR of 5.1% during the forecast period. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals as well as small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease trial costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 (coronavirus) and the increasing demand for developing a suitable treatment for the same is driving the market growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288 therapeutics and 106 vaccines in development. Out of this, nearly 7.0% therapeutics are in Phase IV, 21.0% in Phase III, 43.0% & 13.0% in Phase II & Phase I respectively.

The pandemic has also resulted in global disruption of traditional onsite clinical trials. Hence, the regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the World Health Organization (WHO) to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device & drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

• Phase III clinical trials dominated the market with a revenue share of 53.0% in 2019. This is attributed to the complexity level associated with this phase

• Interventional design segment accounted for the largest market share of 45.6% in 2019 in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

• North America held 51.2% of market share in 2019. Favorable government initiatives and presence of large numbers of players in U.S. offerings advanced services are responsible for the growth

• Asia Pacific is expected to expand at the fastest CAGR of 6.1% over the forecast period owing to the increasing patient pool and cost efficient services

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.3.1. Therapeutics in development
3.3.2. Vaccines in development
3.4. Fast track of clinical trials
3.4.1. FDA initiative –CTPA
3.4.2. UK initiative –ACCORD
3.4.3. ASIA Pacific initiative – DCGI
3.4.4. University of Pittsburgh School of Medicine-UPMC
3.5. Solidarity clinical trials
3.5.1. Participation in solidarity trials
3.5.2. Solidarity clinical trial for vaccines
3.6. Virtual clinical trials
3.6.1. In-home clinical services
3.7. COVID-19 impact on clinical trials
3.7.1. Companies with phase 1 trial disruption
3.7.2. Companies with phase 2 trial disruption
3.7.3. Companies with phase 3 trial disruption
3.8. Market Dynamics
3.8.1. Market Driver Analysis
3.8.1.1. Increasing research and development promoting outsourcing
3.8.1.2. Adoption of new technology in clinical research
3.8.1.3. Increasing prevalence of chronic disease
3.8.1.4. Globalization of clinical trials
3.8.2. Market Restraint Analysis
3.8.2.1. Stringent regulatory policies for patient enrollment
3.8.2.2. Lack of skilled workforce in clinical research
3.8.3. Industry Challenges
3.8.3.1. Rising cost of clinical trial
3.9. Clinical Trials: Market Analysis Tools
3.9.1. Industry Analysis – Porter’s
3.9.1.1. Supplier Power
3.9.1.2. Buyer Power
3.9.1.3. Substitution Threat
3.9.1.4. Threat from new entrant
3.9.1.5. Competitive rivalry
3.9.2. PESTEL Analysis
3.9.2.1. Political Landscape
3.9.2.2. Environmental Landscape
3.9.2.3. Social Landscape
3.9.2.4. Technology Landscape
3.9.2.5. Legal Landscape
3.9.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, by Phase, 2016 – 2027 (USD Million)
4.1. Definitions & Scope
4.2. Phase market share analysis, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027for the following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 – 2027 (USD Million)
5.1. Definitions & Scope
5.2. Study Design market share analysis, 2019 & 2027
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, By Study Design, 2016 to 2027
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 – 2027 (USD Million)
6.1. Definitions & Scope
6.2. Indication market share analysis, 2019 & 2027
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, By Indication, 2016 to 2027
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
6.5.1. Autoimmune/inflammation
6.5.2. Pain management
6.5.3. Oncology
6.5.4. CNS condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Regional Market Analysis, by Phase, 2016 – 2027 (USD Million)
7.1. Definitions & Scope
7.2. Regional Market Share Analysis, 2019 & 2027
7.3. Regional Market Dashboard
7.4. Regional Market Snapshot
7.5. Regional Market Share, 2019
7.6. Market Size, & Forecasts, and Trend Analysis, 2016 to 2027:
7.7. North America
7.7.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.7.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.4. Market estimates and forecast, By Indication, 2016 – 2027 (USD Million)
7.7.5. U.S.
7.7.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.5.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.7.6. Canada
7.7.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.7.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.7.6.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8. Europe
7.8.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.8.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.4. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8.5. Germany
7.8.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.5.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8.6. UK
7.8.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.6.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8.7. France
7.8.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.7.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8.8. Italy
7.8.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.8.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.8.9. Spain
7.8.9.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.8.9.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.8.9.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9. Asia Pacific
7.9.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.9.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.4. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9.5. China
7.9.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.5.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9.6. Japan
7.9.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.6.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9.7. India
7.9.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.7.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9.8. Australia
7.9.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.8.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.9.9. South Korea
7.9.9.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.9.9.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.9.9.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.10. Latin America
7.10.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.10.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.10.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.10.4. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.10.5. Brazil
7.10.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.10.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.10.5.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.10.6. Mexico
7.10.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.10.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.10.6.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.10.7. Argentina
7.10.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.10.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.10.7.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.10.8. Colombia
7.10.8.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.10.8.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.10.8.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.11. Middle East and Africa
7.11.1. Market estimates and forecast, by country, 2016 – 2027 (USD Million)
7.11.2. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.11.3. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.11.4. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.11.5. South Africa
7.11.5.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.11.5.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.11.5.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.11.6. Saudi Arabia
7.11.6.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.11.6.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.11.6.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
7.11.7. UAE
7.11.7.1. Market estimates and forecast, by phase, 2016 – 2027 (USD Million)
7.11.7.2. Market estimates and forecast, by study design, 2016 – 2027 (USD Million)
7.11.7.3. Market estimates and forecast, by indication, 2016 – 2027 (USD Million)
Chapter 8. Clinical Trials Market– Competitive Analysis
8.1. Key companies profiled
8.1.1. IQVIA
8.1.1.1. Company Overview
8.1.1.2. Financial Performance
8.1.1.3. Product Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. PAREXEL International Corporation
8.1.2.1. Company Overview
8.1.2.2. Financial Performance
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Pharmaceutical Product Development, LLC
8.1.3.1. Company Overview
8.1.3.2. Financial Performance
8.1.3.3. Product Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. Charles River Laboratory
8.1.4.1. Company Overview
8.1.4.2. Financial Performance
8.1.4.3. Product Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. ICON Plc
8.1.5.1. Company Overview
8.1.5.2. Financial Performance
8.1.5.3. Product Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Wuxi AppTec Inc
8.1.6.1. Company Overview
8.1.6.2. Financial Performance
8.1.6.3. Product Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. PRA Health Sciences
8.1.7.1. Company Overview
8.1.7.2. Financial Performance
8.1.7.3. Product Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. SGS SA
8.1.8.1. Company Overview
8.1.8.2. Financial Performance
8.1.8.3. Product Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Syneos Health
8.1.9.1. Company Overview
8.1.9.2. Financial Performance
8.1.9.3. Product Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Chiltern International Ltd
8.1.10.1. Company Overview
8.1.10.2. Financial Performance
8.1.10.3. Product Benchmarking
8.1.10.4. Strategic Initiatives
8.1.11. Eli Lilly and Company
8.1.11.1. Company Overview
8.1.11.2. Financial Performance
8.1.11.3. Product Benchmarking
8.1.11.4. Strategic Initiatives
8.1.12. Novo Nordisk A/S
8.1.12.1. Company Overview
8.1.12.2. Financial Performance
8.1.12.3. Product Benchmarking
8.1.12.4. Strategic Initiatives
8.1.13. Pfizer
8.1.13.1. Company Overview
8.1.13.2. Financial Performance
8.1.13.3. Product Benchmarking
8.1.13.4. Strategic Initiatives
8.1.14. Clinipace
8.1.14.1. Company Overview
8.1.14.2. Financial Performance
8.1.14.3. Product Benchmarking
8.1.14.4. Strategic Initiatives  

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Clinical Trials Market, By Region 2016 - 2027 (USD Million)
Table 4 Global Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 5 Global Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 7 Global Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 8 North America Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 9 North America Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 10 North America Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 12 North America Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 13 U.S. Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 14 U.S. Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 16 U.S. Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 17 Canada Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 18 Canada Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 20 Canada Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 21 Europe Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 22 Europe Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 23 Europe Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 25 Europe Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 26 UK Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 27 UK Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 29 UK Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 30 Germany Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 31 Germany Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 33 Germany Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 34 France Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 35 France Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 37 France Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 38 Italy Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 39 Italy Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 41 Italy Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 42 Spain Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 43 Spain Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 45 Spain Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 46 Asia Pacific Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 47 Asia Pacific Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 48 Asia Pacific Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 50 Asia Pacific Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 51 India Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 52 India Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 54 India Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 55 Japan Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 56 Japan Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 58 Japan Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 59 China Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 60 China Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 62 China Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 63 Australia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 64 Australia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 66 Australia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 67 South Korea Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 68 South Korea Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 70 South Korea Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 71 Latin America Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 72 Latin America Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 73 Latin America Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 75 Latin America Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 76 Brazil Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 77 Brazil Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 79 Brazil Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 80 Mexico Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 81 Mexico Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 83 Mexico Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 84 Argentina Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 85 Argentina Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 87 Argentina Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 88 Colombia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 89 Colombia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 91 Colombia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 92 MEA Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
Table 93 MEA Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 94 MEA Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 96 MEA Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 97 South Africa Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 98 South Africa Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 100 South Africa Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 101 Saudi Arabia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 102 Saudi Arabia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 104 Saudi Arabia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
Table 105 UAE Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
Table 106 UAE Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
Table 108 UAE Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[臨床試験の世界市場2020-2027:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別、疾患別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆